The prevalence, incidence, prognosis, and associated conditions of resistant hypertension

Seminars in Nephrology

Volumn 34, Issue 3, 2014, Pages 247-256

  Vega, Joshua ^a   Bisognano, John D ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Associated conditions; Epidemiology; Incidence; Prevalence; Resistant hypertension

Indexed keywords

AMLODIPINE; ATENOLOL; LOSARTAN; TRANDOLAPRIL; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

ALCOHOL CONSUMPTION; AMBULATORY CARE; BLOOD PRESSURE REGULATION; BODY MASS; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; DRUG EXPOSURE; HUMAN; INCIDENCE; LIFESTYLE; MEAN ARTERIAL PRESSURE; MEDICAL RECORD; POPULATION RESEARCH; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; RESISTANT HYPERTENSION; REVIEW; SYSTOLIC BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG RESISTANCE; HYPERTENSION; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; DRUG RESISTANCE; HUMANS; HYPERTENSION; INCIDENCE; PREVALENCE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84904018621     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.04.002     Document Type: Review

References (49)

1. Perkovic V., Huxley R., Wu Y., Prabhakaran D., MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007, 50:991-997.
2. Egan B.M., Zhao Y., Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303:2043-2050.
3. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
4. Cushman W.C., Ford C.E., Cutler J.A., Margolis K.L., Davis B.R., Grimm R.H., et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4:393-404.
5. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
6. Pimenta E., Gaddam K.K., Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich) 2008, 10:239-244.
7. Sarafidis P.A. Epidemiology of resistant hypertension. J Clin Hypertens (Greenwich) 2011, 13:523-528.
8. Sarafidis P.A., Georgianos P., Bakris G.L. Resistant hypertension--its identification and epidemiology. Nat Rev Nephrol 2013, 9:51-58.
9. Yakovlevitch M., Black H.R. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991, 151:1786-1792.
10. Garg J.P., Elliott W.J., Folker A., Izhar M., Black H.R., Service R.U.H. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005, 18:619-626.
11. De Nicola L., Borrelli S., Gabbai F.B., Chiodini P., Zamboli P., Iodice C., et al. Burden of resistant hypertension in hypertensive patients with non-dialysis chronic kidney disease. Kidney Blood Press Res 2011, 34:58-67.
12. Acelajado M.C., Pisoni R., Dudenbostel T., Dell'Italia L.J., Cartmill F., Zhang B., et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012, 14:7-12.
13. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
14. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., Marks R.G., Kowey P., Messerli F.H., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805-2816.
15. Black H.R., Elliott W.J., Grandits G., Grambsch P., Lucente T., White W.B., et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073-2082.
16. Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
17. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
18. Hanselin M.R., Saseen J.J., Allen R.R., Marrs J.C., Nair K.V. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension 2011, 58:1008-1013.
19. McAdam-Marx C., Ye X., Sung J.C., Brixner D.I., Kahler K.H. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther 2009, 31:1116-1123.
20. de la Sierra A., Segura J., Banegas J.R., Gorostidi M., de la Cruz J.J., Armario P., et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011, 57:898-902.
21. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011, 57:1076-1080.
22. Egan B.M., Zhao Y., Axon R.N., Brzezinski W.A., Ferdinand K.C. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011, 124:1046-1058.
23. Chapman N., Dobson J., Wilson S., Dahlof B., Sever P.S., Wedel H., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
24. Pimenta E., Calhoun D.A. Resistant hypertension and aldosteronism. Curr Hypertens Rep 2007, 9:353-359.
25. Daugherty S.L., Powers J.D., Magid D.J., Tavel H.M., Masoudi F.A., Margolis K.L., et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012, 125:1635-1642.
26. Gupta A.K., Nasothimiou E.G., Chang C.L., Sever P.S., Dahlof B., Poulter N.R., et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011, 29:2004-2013.
27. Sarafidis P.A., Bakris G.L. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich) 2008, 10:130-139.
28. Mazzaglia G., Mantovani L.G., Sturkenboom M.C., Filippi A., Trifiro G., Cricelli C., et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005, 23:2093-2100.
29. Van Wijk B.L., Klungel O.H., Heerdink E.R., de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005, 23:2101-2107.
30. Oliveria S.A., Lapuerta P., McCarthy B.D., L'Italien G.J., Berlowitz D.R., Asch S.M. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002, 162:413-420.
31. Brown M.A., Buddle M.L., Martin A. Is resistant hypertension really resistant?. Am J Hypertens 2001, 14:1263-1269.
32. Pierdomenico S.D., Lapenna D., Bucci A., Di Tommaso R., Di Mascio R., Manente B.M., et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005, 18:1422-1428.
33. Nishizaka M.K., Pratt-Ubunama M., Zaman M.A., Cofield S., Calhoun D.A. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005, 18:805-812.
34. Kaplan N.M. Resistant hypertension. J Hypertens 2005, 23:1441-1444.
35. Hall J.E. The kidney, hypertension, and obesity. Hypertension 2003, 41:625-633.
36. Henningsen N.C., Ohlsson O., Mattiasson I., Trell E., Kristensson H., Hood B. Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males. Acta Med Scand 1980, 207:245-251.
37. Whelton A., White W.B., Bello A.E., Puma J.A., Fort J.G., Investigators S.-V. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002, 90:959-963.
38. Calhoun D.A., Nishizaka M.K., Zaman M.A., Thakkar R.B., Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
39. Douma S., Petidis K., Doumas M., Papaefthimiou P., Triantafyllou A., Kartali N., et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008, 371:1921-1926.
40. Hannila-Handelberg T., Kontula K., Tikkanen I., Tikkanen T., Fyhrquist F., Helin K., et al. Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertension. BMC Med Genet 2005, 6:4.
41. Ho H., Pinto A., Hall S.D., Flockhart D.A., Li L., Skaar T.C., et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005, 45:294-298.
42. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
43. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Ford C.E., et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334:13-18.
44. Cuspidi C., Macca G., Sampieri L., Michev I., Salerno M., Fusi V., et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001, 19:2063-2070.
45. Salles G.F., Cardoso C.R., Muxfeldt E.S. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008, 168:2340-2346.
46. Boggia J., Li Y., Thijs L., Hansen T.W., Kikuya M., Bjorklund-Bodegard K., et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007, 370:1219-1229.
47. Muxfeldt E.S., Cardoso C.R., Salles G.F. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med 2009, 169:874-880.
48. Collins R., Peto R., MacMahon S., Hebert P., Fiebach N.H., Eberlein K.A., et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335:827-838.
49. Kandzari D.E., Bhatt D.L., Sobotka P.A., O'Neill W.W., Esler M., Flack J.M., et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012, 35:528-535.